Prospect Venture Partners is a venture capital firm based in Palo Alto, California. Founded in 1997, the firm has more than $1B of capital under management through its three life sciences funds: Prospect Venture Partners I, Prospect Venture Partners II, and Prospect Venture Partners III.
David Schnell MD and Russell Hirsch MD, PhD, currently serve as managing directors for the three Prospect Venture Partners funds and the firm was co-founded by Schnell and the late Alex Barkas PhD.
Investments include:
- Amicus Therapeutics (NASDAQ: FOLD)
- Amira Pharmaceuticals (NYSE: BMS acquired)
- Aveo Pharmaceuticals (NASDAQ: AVEO)
- Cabochon (Merz acquired)
- Complete Genomics (NASDAQ: GNOM)
- Gloucester Pharmaceuticals (NASDAQ: CELG acquired)
- Hansen Medical (NASDAQ: HNSN)
- Idun Pharmaceuticals (NYSE: PFE acquired)
- Infinity Pharmaceuticals (NASDAQ: INFI)
- Insmed (NASDAQ: INSM)
- Jazz Pharmaceuticals (NASDAQ: JAZZ)
- Kythera Biopharmaceuticals (NYSE: AGN acquired)
- Millennium Pharmaceuticals (Takeda Pharmaceutical acquired)
- Nanosys
- NGM Biopharmaceuticals
- Ninepoint Medical
- Novacept (NASDAQ: HOLX acquired)
- Opus Medical (NASDAQ: ARTC acquired)
- Portola Pharmaceuticals (NASDAQ: PTLA)
- Rinat Neuroscience (NYSE: PFE acquired)
- Senomyx (NASDAQ: SNMX)
- SentreHeart
- SurgRx (NYSE: JNJ acquired)
- Tercica (EURO: IPN acquired)
- Topica Pharmaceuticals (NYSE: VRX acquired via Medicis)
- Trubion (NYSE: EBS acquired)